{
  "source": "PA-Notification-Signifor.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1093-12\nProgram Prior Authorization/Notification\nMedication Signifor® (pasireotide diaspartate)\nP&T Approval Date 2/2013, 5/2013, 11/2013, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018,\n9/2019, 9/2020, 9/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSignifor (pasireotide diaspartate) is a somatostatin analog indicated for the treatment of adult\npatients with Cushing’s disease for whom pituitary surgery is not an option or has not been\ncurative.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Signifor will be approved based on both of the following criteria:\na. Diagnosis of endogenous Cushing’s disease (i.e., hypercortisolism is not a result of\nchronic administration of high dose glucocorticoids)\n-AND-\nb. One of the following:\n(1) Pituitary surgery has not been curative for the patient\n(2) Patient is not a candidate for pituitary surgery\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Signifor will be approved based on the following criterion:\na. Documentation of positive clinical response to Signifor therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Signifor [package insert]. Bridgewater, NJ: Recordati Rare Diseases, Inc.; July 2024.\nProgram Prior Authorization/Notification - Signifor (pasireotide diaspartate)\nNotification\nChange Control\n2/2013 ",
    " Signifor [package insert]. Bridgewater, NJ: Recordati Rare Diseases, Inc.; July 2024.\nProgram Prior Authorization/Notification - Signifor (pasireotide diaspartate)\nNotification\nChange Control\n2/2013 New program.\n5/2013 Initial authorization period revised based upon consultant feedback.\n11/2013 Formatting update. Removal of dose information in Background\nSection.\n11/2014 Annual review with no change to coverage.\n11/2015 Annual review. Updated background info. Changed authorization\nperiod from 3 months to 6 months. Updated references.\n9/2016 Annual review. No change to coverage criteria.\n9/2017 Annual review with no changes to coverage criteria.\n9/2018 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2019 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2020 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2021 Annual review with no changes to coverage criteria. Updated\nreference.\n10/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n10/2023 Annual review with no changes to coverage criteria.\n10/2024 Annual review. Updated initial authorization duration to 12 months and\nupdated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}